FDA Premarket Approval (PMA) — Class III Device Approval
Record ID: biomedical-reg-003 (Biomedical · regulation · license) Issuing body / enforcer: U.S. Food and Drug Administration (FDA), CDRH Jurisdiction: United States
1. What it is
The PMA is FDA's most stringent device marketing application, required for Class III devices — those that support or sustain human life, are of substantial importance in preventing impairment of health, or present a potential unreasonable risk of illness or injury. Unlike a 510(k) clearance, a PMA is an approval based on valid scientific evidence (typically including clinical data) that the device is safe and effective for its intended use. It is a full scientific review, not a comparison to a predicate.
Engineers must know the clearance-vs-approval distinction cold: saying a PMA device is "510(k) cleared" or a 510(k) device is "FDA approved" is a misbranding-adjacent error that appears in marketing materials with depressing regularity.
2. Scope and who it applies to
- Applies to Class III devices: implantables (pacemakers, heart valves, neurostimulators), life-supporting devices, and novel high-risk technologies. Some pre-amendments Class III devices historically went through 510(k); FDA has been calling the remaining ones up to PMA over time.
- Trigger: No marketing until FDA issues the PMA approval order. Clinical investigation of a significant-risk device first requires an IDE (Investigational Device Exemption) — the clinical trial itself is regulated.
- HDE variant (Humanitarian Device Exemption): For devices treating conditions affecting fewer than 8,000 U.S. patients per year — approval requires safety and probable benefit (effectiveness not required to the PMA standard), with profit restrictions. The HDE is the realistic pathway for ultra-rare-condition devices.
3. Key requirements and compliance obligations
- Valid scientific evidence: Well-controlled clinical investigations are the norm; the application includes device description, nonclinical studies (bench, animal, biocompatibility, sterility), clinical study reports with statistical analysis, manufacturing information (QMSR-compliant manufacturing — FDA typically inspects manufacturing facilities before PMA approval, unlike 510(k)), and labeling.
- Manufacturing inspection: Pre-approval inspection of the manufacturing site(s) is standard for original PMAs — the QMS must be inspection-ready before approval, which is the major operational difference from 510(k).
- Review mechanics (MDUFA V goals, catalogue-verified): 180 FDA days without advisory committee, 320 FDA days with panel review. Advisory (panel) meetings are public — the sponsor's data and FDA's review memos become public record, a strategic consideration.
- Supplements: Post-approval changes are managed through PMA supplements — 180-day, real-time, 30-day notice, and annual-report categories depending on the change's significance. Engineers must classify every design/manufacturing change into the correct supplement pathway; getting this wrong is a recurring inspection finding.
- Post-approval study (PAS) and postmarket surveillance: FDA routinely imposes PAS as a condition of approval for implantables — long-term follow-up obligations that the engineering/clinical team must resource for years.
- User fees (FY 2026, catalogue-verified): Standard original PMA fee $579,272 (small-business and HDE reductions apply; confirm at fda.gov — fees reset October 1 annually).
4. Penalties and consequences of non-compliance
- Marketing a Class III device without PMA approval = adulterated/misbranded; full FD&C Act enforcement arsenal (seizure, injunction, criminal prosecution).
- Failure to conduct required post-approval studies or report under PMA conditions can lead to withdrawal of approval.
- Off-label promotion of a PMA device beyond its approved indications is misbranding — the approved labeling is the legal boundary of promotion.
- Data integrity failures in the PMA (fabricated or misrepresented clinical data) have drawn criminal prosecution of individuals, not just corporate penalties.
5. Version and live changes — verified
- The PMA framework is statutory; MDUFA V (2023–2027) sets current review goals and fees.
- FY 2026 standard fee $579,272; 180/320 FDA-day review goals (catalogue-verified).
- Flag: MDUFA VI negotiations will set the next user-fee cycle's goals and fees — watch for changes effective FY 2028. Confirm all figures at fda.gov before budgeting.
6. Related certifications (Biomedical)
From the catalogue (record_type=certification, importance=license/flagship, Biomedical):
- RAC-Devices (RAPS) — PMA/IDE strategy, valid scientific evidence standards, and supplement pathways are core RAC content.
- CCE — clinical-engineering practice touches PMA devices in service but not the approval process.
- PE — no biomedical PE exam; not tested.
7. Honest flags
- Fees and review goals are point-in-time FY 2026 figures; both move with MDUFA cycles.
- The HDE patient-population threshold (<8,000/year) is statutory but should be confirmed in current statute/guidance before advising — thresholds are occasionally amended.
Original ETS reference writing, verified against public sources on 2026-09-30. Thin sourcing is flagged inline. Not legal advice — confirm current editions with the issuing body.